Phase II study of spirogermanium in patients with advanced carcinoma of the cervix.
D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005857:Germanium / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009942:Organometallic Compounds; D011379:Prognosis; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D009942:Organometallic Compounds; D013141:Spiro Compounds; D005857:Germanium; C026818:spirogermanium